Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has announced a £4.8 million extension to its Series C financing, in addition to the £14m secured in March 2025.

With existing operations in the US and an extensive portfolio of FDA-cleared AI imaging solutions, the additional capital will enable Brainomix to further expand in the US market as the company advances deployment of its AI imaging platforms, Brainomix 360 Stroke and e-Lung, across multiple hospitals.

The extension round was led by existing investors, Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, and includes participation from a new US-based investor, Modi Ventures.